The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor
For citations:
The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor. Pediatric pharmacology. 2023;20(1):92. (In Russ.)
Views:
287
Email this article 